Veracyte Inc. (VCYT)
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
